Thu, 18th Dec 2014 13:15
** Biotechnology company's shares up 12 pct at$3.75 premarket
** Says shingles vaccine developed by partnerGlaxoSmithKline Plc met main goal in a late-stage study
** The vaccine, HZ/su, combines protein found on virus thatcauses shingles with a component from Agenus
** Agenus to get royalties on potential commercial sales ofHZ/su
** Up to Wednesday's close, stock had risen 8 pct this year
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a...
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:
CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U....
FTSE 100 down 0.3%, FTSE 250 off 0.2% *
(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal...
Glaxosmithkline (GSK)